JP2009535430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535430A5 JP2009535430A5 JP2009510053A JP2009510053A JP2009535430A5 JP 2009535430 A5 JP2009535430 A5 JP 2009535430A5 JP 2009510053 A JP2009510053 A JP 2009510053A JP 2009510053 A JP2009510053 A JP 2009510053A JP 2009535430 A5 JP2009535430 A5 JP 2009535430A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor antagonist
- glucocorticoid receptor
- administered
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims description 58
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 41
- -1 steroid compound Chemical class 0.000 claims description 30
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
- 102000000588 Interleukin-2 Human genes 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 12
- 150000003431 steroids Chemical class 0.000 claims description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- YMROUWDKBBTAPS-UHFFFAOYSA-N (2-methylpyridin-3-yl)methanamine Chemical compound CC1=NC=CC=C1CN YMROUWDKBBTAPS-UHFFFAOYSA-N 0.000 claims description 2
- NTIQESMLXCAPAT-FGRBEGKDSA-N (2r,4as,10ar)-4a-benzyl-1-(2-chloroethynyl)-2,3,4,9,10,10a-hexahydro-1h-phenanthrene-2,7-diol Chemical compound C([C@]12CC[C@H](C([C@H]2CCC=2C1=CC=C(O)C=2)C#CCl)O)C1=CC=CC=C1 NTIQESMLXCAPAT-FGRBEGKDSA-N 0.000 claims description 2
- WDSPVCXWXOIFRA-HUVFLSCGSA-N (2r,4as,10ar)-4a-benzyl-2-prop-1-ynyl-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol Chemical compound C([C@]12CC[C@](C[C@H]2CCC=2C1=CC=C(O)C=2)(O)C#CC)C1=CC=CC=C1 WDSPVCXWXOIFRA-HUVFLSCGSA-N 0.000 claims description 2
- BLOFVNRXXISVRW-SPIKMXEPSA-N (z)-but-2-enedioic acid;2-[4-[2-[tris(4-chlorophenyl)methoxy]ethyl]piperazin-1-yl]ethanol Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(CCO)CCN1CCOC(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BLOFVNRXXISVRW-SPIKMXEPSA-N 0.000 claims description 2
- PJDWNSYGMXODTB-UHFFFAOYSA-N 1,2,3,4,4a,4b,5,6-octahydrophenanthrene Chemical compound C1=CCCC2C(CCCC3)C3=CC=C21 PJDWNSYGMXODTB-UHFFFAOYSA-N 0.000 claims description 2
- YIWVYEMVUUIDFI-UHFFFAOYSA-N 1-[(2-chlorophenyl)-diphenylmethyl]-2-methylimidazole Chemical group CC1=NC=CN1C(C=1C(=CC=CC=1)Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 YIWVYEMVUUIDFI-UHFFFAOYSA-N 0.000 claims description 2
- NQHBVDBKRQTWEH-UHFFFAOYSA-N 1-[(2-chlorophenyl)-diphenylmethyl]-3,5-dimethylpyrazole Chemical compound N1=C(C)C=C(C)N1C(C=1C(=CC=CC=1)Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 NQHBVDBKRQTWEH-UHFFFAOYSA-N 0.000 claims description 2
- XKDZMKALJIYVNU-UHFFFAOYSA-N 1h-benzo[f]indazole Chemical compound C1=CC=C2C=C3C=NNC3=CC2=C1 XKDZMKALJIYVNU-UHFFFAOYSA-N 0.000 claims description 2
- ACRGIRLCXXEJCS-UHFFFAOYSA-N 1h-indole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1C=CN2 ACRGIRLCXXEJCS-UHFFFAOYSA-N 0.000 claims description 2
- PHQYCUVRCSXPBF-UHFFFAOYSA-N 2,7-difluoro-9-phenyl-9-(5-sulfanylidene-1,2-dihydro-1,2,4-triazol-3-yl)-2h-fluoren-1-one Chemical group O=C1C(F)C=CC(C2=CC=C(F)C=C22)=C1C2(C=1C=CC=CC=1)C1=NC(S)=NN1 PHQYCUVRCSXPBF-UHFFFAOYSA-N 0.000 claims description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims description 2
- AGUNPFIFLDXKPR-UHFFFAOYSA-N 2-trityl-1h-imidazole Chemical compound C1=CNC(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 AGUNPFIFLDXKPR-UHFFFAOYSA-N 0.000 claims description 2
- MLRAJZNPKPVUDQ-UHFFFAOYSA-N 3-sulfanyl-1,2-dihydrotriazole Chemical compound SN1NNC=C1 MLRAJZNPKPVUDQ-UHFFFAOYSA-N 0.000 claims description 2
- DFXBSTBGWCEKSD-UHFFFAOYSA-N 4-[2-[tris(4-chlorophenyl)methoxy]ethyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)OCCN1CCOCC1 DFXBSTBGWCEKSD-UHFFFAOYSA-N 0.000 claims description 2
- POAVRNPUPPJLKZ-UHFFFAOYSA-N 6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-ol Chemical compound C1CC2=CC=CC=C2C(O)C2=CC=CC=C21 POAVRNPUPPJLKZ-UHFFFAOYSA-N 0.000 claims description 2
- BEUDCHGZCTUAOG-UHFFFAOYSA-N 6h-benzo[c]chromene Chemical class C1=CC=C2COC3=CC=CC=C3C2=C1 BEUDCHGZCTUAOG-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 206010054089 Depressive symptom Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- LVBREWKFQYTCQO-UHFFFAOYSA-N N1=CC=C(C=C1)CNC(=O)C1=CC=2C=CC3=CC=CC=C3C2C=C1 Chemical compound N1=CC=C(C=C1)CNC(=O)C1=CC=2C=CC3=CC=CC=C3C2C=C1 LVBREWKFQYTCQO-UHFFFAOYSA-N 0.000 claims description 2
- AFMXNPUMXZCVGU-CWNVBEKCSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] methanesulfonate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COS(C)(=O)=O)[C@@H]4[C@@H]3CCC2=C1 AFMXNPUMXZCVGU-CWNVBEKCSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 150000001448 anilines Chemical class 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical group ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- FXKHIMPBOCLMFP-UHFFFAOYSA-N cyclopenta[f]indazole Chemical compound C=1C2=CN=NC2=CC2=CC=CC2=1 FXKHIMPBOCLMFP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 2
- 229960003248 mifepristone Drugs 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 150000004961 triphenylmethanes Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 45
- 230000001548 androgenic effect Effects 0.000 claims 1
- 239000003098 androgen Substances 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79726506P | 2006-05-02 | 2006-05-02 | |
| PCT/US2007/068044 WO2007131041A2 (en) | 2006-05-02 | 2007-05-02 | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535430A JP2009535430A (ja) | 2009-10-01 |
| JP2009535430A5 true JP2009535430A5 (https=) | 2011-06-16 |
Family
ID=38668513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510053A Withdrawn JP2009535430A (ja) | 2006-05-02 | 2007-05-02 | Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2012796A4 (https=) |
| JP (1) | JP2009535430A (https=) |
| AU (1) | AU2007248059A1 (https=) |
| CA (1) | CA2649894A1 (https=) |
| WO (1) | WO2007131041A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110702T1 (hr) | 2007-02-02 | 2011-10-31 | Pfizer Products Inc. | Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora |
| EP2114888B1 (en) * | 2007-02-02 | 2010-11-10 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| EP4406611A3 (en) * | 2016-01-11 | 2024-10-23 | Dignity Health | Modulators of zinc activated cation channel |
| CN115053861A (zh) * | 2022-06-30 | 2022-09-16 | 南方医科大学南方医院 | 一种基于免疫激活的精神分裂症动物模型的构建方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE332696T1 (de) * | 1997-10-06 | 2006-08-15 | Univ Leland Stanford Junior | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen |
| KR20050038580A (ko) * | 2001-10-26 | 2005-04-27 | 악조 노벨 엔.브이. | 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도 |
| WO2003043640A2 (en) * | 2001-11-23 | 2003-05-30 | Akzo Nobel N.V. | Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| JP2006508951A (ja) * | 2002-11-05 | 2006-03-16 | コーセプト セラピューティクス， インコーポレイテッド | 片頭痛を処置するための方法 |
-
2007
- 2007-05-02 JP JP2009510053A patent/JP2009535430A/ja not_active Withdrawn
- 2007-05-02 CA CA002649894A patent/CA2649894A1/en not_active Abandoned
- 2007-05-02 AU AU2007248059A patent/AU2007248059A1/en not_active Abandoned
- 2007-05-02 WO PCT/US2007/068044 patent/WO2007131041A2/en not_active Ceased
- 2007-05-02 EP EP07783115A patent/EP2012796A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020065259A1 (en) | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | |
| JP2009535430A5 (https=) | ||
| US20120184515A1 (en) | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases | |
| CN102753565B (zh) | 孕酮受体拮抗剂 | |
| US20120232042A1 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases | |
| JP2011518811A5 (https=) | ||
| JP2010509386A5 (https=) | ||
| JP2009102413A (ja) | 抗神経病薬誘導性体重増加を予防するための方法 | |
| AU2017251837B2 (en) | Compositions and Methods for Non-Toxic Delivery of Antiprogestins | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| JP2006507311A5 (https=) | ||
| JP2010507685A5 (https=) | ||
| EP2576582B1 (en) | Treatment of muscular dystrophy | |
| KR20190122239A (ko) | 글루코코르티코이드 수용체 조정제 및 cyp3a 억제제의 병용 투여 | |
| JP2022513237A5 (https=) | ||
| JP2015514700A5 (https=) | ||
| JP2006516651A5 (https=) | ||
| AU2005265174A1 (en) | Estrogen receptor modulators | |
| RU2363466C2 (ru) | Способ и набор для лечения и профилактики злокачественных опухолей женской репродуктивной системы с применением 9-оксоакридин-10-уксусной кислоты, и/или ее соли, и/или ее сложного эфира | |
| JP4647909B2 (ja) | 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用 | |
| JP2005513024A (ja) | グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療 | |
| CA2674440A1 (en) | Methods for improved stability of steroid derivatives | |
| RU2010100337A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, КОТОРЫЕ ВКЛЮЧАЮТ ПРОИЗВОДНОЕ | |
| Jin et al. | Synthesis and identification of novel 11β-aryl-4′, 5′-dihydrospiro [estra-4, 9-diene-17β, 4′-oxazole] analogs with dissociated antiprogesterone activities | |
| AU2011345341A1 (en) | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions |